Kashiv Specialty Pharmaceuticals (KSP) is a wholly-owned subsidiary of Kashiv Biosciences, formed to develop complex generics, innovative drug delivery platforms, and novel 505(b)(2) drugs.
KSP is a fully integrated pharmaceutical company with capabilities to develop and manufacture innovative medicines, next-generation drug delivery technologies and clinically differentiated specialty pharmaceutical products.
We are built on patient-focused innovation and development of advanced drug delivery platforms with application in a wide variety of molecules to improve their clinical activity.
We identify unmet medical needs in various therapeutic areas and develop clinically differentiated products and to provide effective, safe, and affordable medicines to improve the overall quality of life for all patients.
Since the star of its operations in 2011, Kashiv under the leadership of top industry formulation scientists has developed several patented next generation oral drug delivery technologies, 15 high-value complex generic products successfully launched by a partner, and a proprietary clinical stage pipeline of five differentiated 505(b)(2) products targeting orphan and severe diseases. Kashiv has a growing pipeline of several new complex generics and new 505(b)(2) candidates undergoing feasibility testing and formulation development.
We are a People-Oriented
We are a fast-growing specialty pharmaceutical company providing an innovative environment and opportunities for professional growth.